{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 14 of 51', 'Study ID RCB: 2020-A00652-37', 'baseline. The therapeutic objective achievement is defined as \"satisfied\" or \"very', 'satisfied\" response on 4 points Likert scale.', '-', 'Level of concordance between the satisfaction level in regard to the therapeutic', 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up', 'visit (52 4 weeks.).', '- Research of predictive factors (among baseline characteristics) of the achievement of the', 'main treatment goal.', '-', 'Percentage of agreement between the physician-reported and the patient-reported', 'dimensions at the first follow-up visit.', '-', 'Rate of patients having changed objective at the 1st follow-up visit (12/ 16 weeks).', '-', 'Percentage of patients who have maintained at 52 + 4 weeks the level of satisfaction', 'achieved at the 1st follow-up visit.', '-', 'PASI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit', '(52 + 4 weeks.).', '-', 'Level of accordance between PASI 90/100 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid.', '-', 'DLQI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit', '52 + 4 weeks.', 'Data sources', \"Patients' data will be collected at day 0, at the 1st follow-up visit (12/16weeks) and at the\", \"2nd follow-up visit at 52 4 weeks according to the physician's practice.\", 'As a prospective study, the following data will be collected during the patient visit:', 'disease history, concomitant treatments, previous anti psoriatic treatment and adverse events.', 'In addition, the following study specific data will be collected: disease severity (PASI score),', 'quality of life questionnaires (DLQI, PSO-TARGET component grid).', 'Study size', 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who', 'consider their target objective as being achieved after 12/16 weeks of treatment as defined', 'by a \"satisfied or very satisfied\" response, assessed on a 4 points Likert scale, among patients', 'with a DLQI total score of 0 or 1).', 'The sample size calculation is based on the following hypotheses', ':', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 15 of 51', 'Study ID RCB: 2020-A00652-37', 'Sensitivity : 90%', 'Absolute precision : 10%', 'Type I error : 5%', 'Power at 80%', 'Prevalence: 80% (estimated rate of patients with a DLQI 0-1 after 12 weeks of', 'treatment.', 'Based on these hypotheses, the sample size needed is estimated at 134 evaluable patients.', 'Assuming 10% of patients will not be evaluable on main criterion, 150 patients have to be', 'included.', 'Data analysis', 'Analysis of the primary endpoint', 'The performance of the PSO-TARGET QoL component grid to assess the treatment impact on', \"the patients' quality of life will be determined by calculating the sensitivity and specificity of\", 'the grid compared to the DLQI (reference). The grid will be validated if both the specificity and', 'sensitivity parameters reach the 85% threshold.', 'Milestones', 'Regulatory Submissions: Q2 2020', 'Start of data collection Q3 2020', 'End of data collection Q2 2022', 'Final report Q4 2022', '5', 'Amendments and Updates', 'None', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}